. 2020 Mar 19;13(4):769–776. doi: 10.1111/cts.12763

Table 3.

Observed and predicted ddQTcF in healthy adults following administration of fostemsavir at 1,200 mg q.d., 2,400 mg b.i.d., and 600 mg b.i.d. ± cobicistat 150 mg q.d.

	FTR 1,200 mg q.d. N = 57	FTR 2,400 mg b.i.d. N = 53	FTR 600 mg b.i.d. N = 16	FTR 600 mg b.i.d. + cobicistat 150 mg q.d. N = 15
ddQTcF upper 90% CI boundary (msec)	6.4 (at 6 hour)	13.3 (at 5 hour)	3.2^a	5.0^a
Mean C_max (ng/mL)	3,584	8,900	2,096^b	3,515^b

FTR

1,200 mg q.d.

N = 57

FTR

2,400 mg b.i.d.

N = 53

FTR

600 mg b.i.d.

N = 16

FTR 600 mg b.i.d. +

cobicistat 150 mg q.d.

N = 15

ddQTcF upper 90% CI boundary (msec)

6.4 (at 6 hour)

13.3 (at 5 hour)

3.2^a

5.0^a

Mean C_max (ng/mL)

3,584

8,900

2,096^b

3,515^b

CI, confidence interval; C_max, peak plasma concentration; ddQTcF, difference vs. placebo for change from baseline in Fridericia‐corrected QT interval; FTR, fostemsavir.

Model‐predicted.

Data from ref. 21